Diabetic Eye Disease
Participation in clinical trials improves diabetes care
The development of new therapies and cures would be impossible without patients volunteering for clinical research studies. In exchange, volunteers often receive care based on the latest research, while gaining the satisfaction of helping others...
Avastin as effective as Eylea for treating central retinal vein occlusion
Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion (CRVO), according to a clinical trial funded by the National Eye Institute (NEI),...
Woman who lost vision to diabetes shares experience to raise awareness
It was Labor Day 2015 when Rosetta Ivey-Foster, a 67-year-old retired bank clerk, learned first-hand how quickly diabetes can deteriorate vision. Swift action restored most of her eyesight.
Diagnosed with type 1 diabetes more than 25 years...
Eye Study Underscores the Long-lasting Benefits of Controlling Diabetes
People with type 2 diabetes who intensively controlled their blood sugar level during the landmark Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial Eye Study were found to have cut their risk of diabetic retinopathy in half in a...
Eylea Outperforms Avastin for Diabetic Macular Edema with Moderate or Worse Vision Loss
A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), but only among...
New Treatment Options, Better Hope of Preventing Vision Loss from Diabetes
This National Diabetes Month, there is some good news for people with eye complications from diabetes. Earlier this month, a network of researchers supported by the National Eye Institute (NEI) found that the drug Lucentis (ranibizumab) can be...
Lucentis Effective for Proliferative Diabetic Retinopathy
A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy. The trial, conducted by the Diabetic Retinopathy Clinical Research...
Study Finds Potential New Drug Target for Diabetic Eye Disease
Researchers funded in part by the National Eye Institute (NEI) have identified a protein involved in an advanced stage of diabetic retinopathy, a diabetic eye disease that threatens vision. The discovery may help explain why current treatments...
Early Tight Blood Glucose Control Reduces Eye Surgeries in People with Type 1 Diabetes
People with type 1 diabetes who intensively control their blood glucose (blood sugar) early in their disease, versus those who do not, are 48 percent less likely to need eye surgery, and the total number of such surgeries is 37 percent less....
Eylea outperforms other drugs for diabetic macular edema with moderate or worse vision loss
In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or...